ES3031468T3 - Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer - Google Patents

Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer

Info

Publication number
ES3031468T3
ES3031468T3 ES18709192T ES18709192T ES3031468T3 ES 3031468 T3 ES3031468 T3 ES 3031468T3 ES 18709192 T ES18709192 T ES 18709192T ES 18709192 T ES18709192 T ES 18709192T ES 3031468 T3 ES3031468 T3 ES 3031468T3
Authority
ES
Spain
Prior art keywords
cabozantinib
atezolizumab
subjects
dose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18709192T
Other languages
English (en)
Spanish (es)
Inventor
Gisela Schwab
Christian Scheffold
Colin Hessel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3031468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of ES3031468T3 publication Critical patent/ES3031468T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES18709192T 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer Active ES3031468T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US201762458447P 2017-02-13 2017-02-13
PCT/US2018/014523 WO2018136796A1 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer

Publications (1)

Publication Number Publication Date
ES3031468T3 true ES3031468T3 (en) 2025-07-09

Family

ID=61569414

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18709192T Active ES3031468T3 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer

Country Status (14)

Country Link
US (2) US11198731B2 (enExample)
EP (1) EP3570840B1 (enExample)
JP (3) JP7222895B2 (enExample)
KR (2) KR20230169458A (enExample)
CN (4) CN110352057A (enExample)
AU (2) AU2018210397B2 (enExample)
BR (1) BR112019015011A2 (enExample)
ES (1) ES3031468T3 (enExample)
IL (1) IL268138B (enExample)
MA (1) MA47310A (enExample)
MX (2) MX389966B (enExample)
UA (1) UA126970C2 (enExample)
WO (1) WO2018136796A1 (enExample)
ZA (1) ZA201904652B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
UA126970C2 (uk) 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
BR112021004126A2 (pt) * 2018-09-05 2021-05-25 Ventria Bioscience Inc. formulação profilática e/ou terapêutica estabilizada e método profilático ou terapêutico
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
TWI923583B (zh) * 2020-04-14 2026-05-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
PH12023550160A1 (en) * 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer
US20230314440A1 (en) * 2020-08-21 2023-10-05 Exelixis, Inc. Method of treating cancer
CA3212604A1 (en) * 2021-03-19 2022-09-22 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법
KR102966277B1 (ko) * 2024-04-25 2026-05-18 한국 한의학 연구원 카보잔티닙을 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
EP2983639A1 (en) * 2013-04-04 2016-02-17 Exelixis, Inc. Drug combinations to treat cancer
EA032757B1 (ru) * 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
US11141413B2 (en) * 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
MA44733A (fr) 2016-04-19 2019-02-27 Exelixis Inc Procédé de traitement du cancer du sein négatif triple
UA126970C2 (uk) * 2017-01-20 2023-03-01 Екселіксіс, Інк. Комбінації кабозантинібу і атезолізумабу для лікування раку

Also Published As

Publication number Publication date
JP2024019720A (ja) 2024-02-09
NZ755494A (en) 2025-06-27
AU2024203472A1 (en) 2024-06-13
WO2018136796A1 (en) 2018-07-26
CN117205312A (zh) 2023-12-12
MA47310A (fr) 2019-11-27
KR102610764B1 (ko) 2023-12-07
JP7222895B2 (ja) 2023-02-15
EP3570840B1 (en) 2025-03-19
CN117205313A (zh) 2023-12-12
BR112019015011A2 (pt) 2020-04-28
US20220056138A1 (en) 2022-02-24
US20190352403A1 (en) 2019-11-21
JP2022121594A (ja) 2022-08-19
KR20190107103A (ko) 2019-09-18
AU2018210397B2 (en) 2024-02-29
KR20230169458A (ko) 2023-12-15
CN117771363A (zh) 2024-03-29
CN110352057A (zh) 2019-10-18
CA3049452A1 (en) 2018-07-26
ZA201904652B (en) 2024-11-27
EP3570840A1 (en) 2019-11-27
UA126970C2 (uk) 2023-03-01
JP2020514311A (ja) 2020-05-21
US11198731B2 (en) 2021-12-14
IL268138A (en) 2019-09-26
IL268138B (en) 2022-08-01
MX389966B (es) 2025-03-20
MX2022001718A (es) 2022-03-11
AU2018210397A1 (en) 2019-07-25
MX2019008032A (es) 2019-12-16

Similar Documents

Publication Publication Date Title
US11198731B2 (en) Combinations of cabozantinib and atezolizumab to treat cancer
JP2025529161A (ja) 活性化ｆｇｆｒ３遺伝子変化を有する固形腫瘍を処置する方法
Adkins et al. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
US20220323445A1 (en) Reducing immunogenicity to pegloticase
JP2020519576A (ja) 肝細胞癌の治療
US20260098087A1 (en) Dosages of emactuzumab
BR112020014574A2 (pt) Composições e métodos para o tratamento do câncer
WO2022089377A1 (en) Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
HK40105136A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40105135A (en) Combinations of cabozantinib and atezolizumab to treat cancer
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
Zhang et al. Efficacy and safety of HIPEC combined with PD-1 and SOX chemotherapy for gastric or oesophagogastric junctional cancer with peritoneal metastasis (HISTORIA): protocol for a prospective, multicentre, single-arm, phase II study
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40124164A (en) Methods of treating solid tumors having activating fgfr3 gene alterations
Chen Study Title: The safety and efficacy of sintilimab combined with platinum-based chemotherapy in neoadjuvant therapy for potentially resectable esophageal cancer: An open-label, single-arm, exploratory clinical study
JP2025532826A (ja) がんの処置のためのｂ－ｒａｆ阻害剤と、抗ｅｇｆｒ抗体との組み合わせ
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法